Keros Therapeutics Prospects Still Strong Despite Cibotercept Hurdles, Wedbush Says
In This Article:
Keros Therapeutics' (KROS) efforts to develop new treatments for pulmonary arterial hypertension rem
Upgrade to read this MT Newswires article and get so much more.
A Silver or Gold subscription plan is required to access premium news articles.